Dr. Anosh Ahmed announces an expansion of his COVID-19 testing services, with new COVID testing contracts now secured and ...

The National Lung Health Alliance (NLHA) is Canada’s leading advocacy network for lung health. Led by the Lung Health Foundation, the alliance includes several organizations: BC Lung Foundation, ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ...

Joybird’s Treehouse is an education-based platform that provides culturally relevant literacy tools for students from pre-kindergarten through 12th grade. Founded by educator Joyce Caraway, the ...

Corza Medical, a leading global medical technology company, today announced the launch of its expanded Onatec Ophthalmic Suture Portfolio. This marks a significant extension of the product range, ...

At the event, physician key opinion leaders will discuss the company’s current indications in neurology and psychiatry. Members of the Axsome management team will provide an overview of the clinical ...

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today ...

YIV-906 increases safety and reduces non-hematological toxicities by cytoprotecting the gastrointestinal tract by reducing GI inflammation (NF-kB, COX2, iNOS, IL-6), promoting damaged tissue repair ...

MPS-I is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme resulting in the accumulation of glycosaminoglycans (GAGs) in multiple ...

The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic ® network, closed the sale of 31 corporate owned and managed clinics and associated ...

TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses ...

Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study ( NCT06962839 ). It will investigate the efficacy, safety and tolerability of ...